ELVN — Enliven Therapeutics Share News
0.000.00%
Last trade - 00:00U.S. RESEARCH ROUNDUP-Biomea Fusion, Enphase Energy, Perion Network
Enliven Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Enliven Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Cheesecake Factory, Netflix, Texas Roadhouse
U.S. STOCKS ON THE MOVE-Rent the Runway, Lumen Technologies, Enliven Therapeutics
U.S. STOCKS ON THE MOVE-Constellation Brands, Nike, Rocket Lab
Enliven Therapeutics jumps after cancer drug shows promise in early trial
Brief: Enliven Therapeutics Announces Positive Proof Of Concept Data From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia
Brief: Enliven Therapeutics Appoints Lori Kunkel To Board Of Directors
Enliven Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Enliven Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Enliven Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Enliven Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Enliven Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview